newsfilter
← Latest News
GlobeNewswire·

Iterum Therapeutics Reports First Quarter 2024 Financial Results

--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and